Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-R3B23
- Development stage
- Preclinical
- Lead developer
- Vrije Universiteit Brussel
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-R3B23 is a targeted radiopharmaceutical consisting of a camelid single-domain antibody (sdAb or Nanobody), R3B23, labeled with the beta-emitting radionuclide Lutetium-177 (177Lu) via a DTPA chelator. The R3B23 nanobody specifically targets the M-protein (paraprotein) expressed by 5T2MM murine multiple myeloma cells. In preclinical research, 177Lu-R3B23 is frequently utilized as a non-targeting control agent to evaluate the specificity and immune-modifying effects of other targeted radionuclide therapies (TRT) in models that do not express the 5T2MM M-protein, such as B16-melanoma. The therapeutic mechanism involves the localized delivery of cytotoxic beta-radiation, which induces DNA damage and subsequent apoptosis in cells expressing the target antigen.
- Other names
- 177Lu-DTPA-R3B23177Lu-DTPA-sdAb R3B23
02
Targets
Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on 177Lu-R3B23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-R3B23.